期刊文献+

继发性与原发性骨髓纤维化骨髓组织形态学观察及临床意义 被引量:8

Morphology of bone marrow in patients with secondary myelofibrosis and primary myelofibrosis and its clinical significance
下载PDF
导出
摘要 目的观察恶性血液病继发骨髓纤维化患者的临床情况和骨髓病理学特征,探讨继发性骨髓纤维化与原发性骨髓纤维化在临床表现及骨髓组织形态的差异。方法对69例继发性骨髓纤维化(SMF)患者分别采用骨髓活检塑料包埋切片HGE(苏木素-吉姆萨-伊红)染色和骨髓涂片Wright染色进行组织与细胞形态学对比观察,并与36例原发性骨髓纤维化纤维化期(PMF-F)患者骨髓组织形态进行回顾性比较分析。结果 69例SMF患者初诊年龄显著低于PMF患者(P<0.05),在初诊时贫血的检出率差异有统计学意义(P<0.05),其他实验室指标包括血红蛋白、白细胞数量、血小板数量没有显著差异。两组病例在骨髓涂片以及骨髓活检的增生程度差异有统计学意义(P<0.05),在骨髓活检网状纤维染色不同级别网状纤维检出率差异有统计学意义(P<0.05)。结论①继发骨髓纤维化的发生年龄小,且多取决于其基础疾病的发生年龄。②继发性骨髓纤维化骨髓涂片和骨髓活检的增生程度与原发性骨髓纤维化相比,增生情况较好,对临床年轻的骨髓纤维化患者及早寻找原发病因,进行鉴别诊断具有重要意义。 Objective To explore the difference of clinical features and morphology between secondary myelofibrosis and primary myelofibrosis.Methods Histopathology analysis of bone marrow by biopsy plastic-embedded sections stained with HGE and by bone marrow smear stained with Wright and clinical features in 69 patients with secondary myelofibrosis(SMF) and 36 patients with primary myelofibrosis(PMF) were reviewed retrospectively.Results The age of SMF patients was significantly lower than that of PMF patients(P〈0.05).The detection rate of mild anemia was significantly different between SMF and PMF(P〈0.05).Other laboratory features including hemoglobin,white blood cell count,and platelet count showed no significant difference.The proliferation of bone marrow smear and bone marrow biopsy were significantly different between SMF and PMF(P〈0.05).And the detection rate of the reticular fiber with Gomori’s stains was also significantly different in bone marrow biopsy between SMF and PMF(P〈0.05).Conclusion The patients with SMF are younger than PMF patients,depending on the age of their underlying diseases.Compared with PMF,the proliferation of bone marrow smears and bone marrow biopsy is better in SMF,which is important to find the original cause of myelofibrosis in young patients and make the differential daignosis.
出处 《山西医科大学学报》 CAS 2012年第6期453-456,F0003,共5页 Journal of Shanxi Medical University
关键词 骨髓纤维化 骨髓涂片 骨髓活检 myelofibrosis; bone marrow biopsy; bone marrow smear
  • 相关文献

参考文献7

  • 1Thiele J, Kvasnicka HM, Facchetti F,et al. European consensus on grading bone marrow fibrosis and assessment of cellularity [ J ]. Haematologica,2005,90 : 1128 - 1132.
  • 2肖志坚.规范和重视原发性骨髓纤维化的诊断和治疗[J].白血病.淋巴瘤,2010,19(9):513-516. 被引量:13
  • 3张振兴(综述),夏珺(审校),沈云峰(审校).原发性骨髓纤维化的诊断和治疗进展[J].国际输血及血液学杂志,2010(1):40-44. 被引量:4
  • 4Lazzarino M, Morra E, Castello A, et al. Myelofibrosis in chronic granulocytic leukaemia: clinicopathologic correlations and prog- nostic significance [ J ]. Br J Haematol, 1986,64 (2) :227 - 240.
  • 5Marisavljevic D, Rolovic Z, Cemerikic V, et al. Myelofibrosis in pri- mary myelodysplastic syndromes: clinical and biological signifi- cance [ J ]. Med Onco1,2004,21 (4) :325 - 331.
  • 6Imbert M, Ngnyen D, Sultan C. Myelodysplastic syndromes (MDS)and acutemyeloid leukemias (AML) with myelofibrosis [ J ]. Leuk Res,1992,16(1) :51 -54.
  • 7McCarthy DM. Annotation. Fibrosis of the bone marrow: content and causes[J]. Br J Haematol,1985 ,59 :1 -7.

二级参考文献20

  • 1Kr(o)ger N,Holler E,Kobbe G,et al.Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis:a prospective,multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.Blood,2009,114:5264-5270.
  • 2Zang DY,Deeg HJ.Allogeneic hematopoietic cell transplantation for patients with myelofibrosis.Curr Opin Hematol,2009,16:140-146.
  • 3Thomas DA,Giles FJ,Albitar M,et al.Thalidomide therapy for myelofibrosis with myeloid metaplasia.Cancer,2006,106:1974-1984.
  • 4Abgrall JF,Guibaud I,Bastie JN,et al.Thalidomide versus placebo in myeloid metaplasia with myelofibrosis:a prospective,randomized,double-blind,multicenter study.Haematologica,2006,91:1027-1032.
  • 5Tefferi A,Cortes J,Verstovsek S,et al.Lenalidomide therapy in myelofibrosis with myeloid metaplasia.Blood,2006,108:1158-1164.
  • 6Quint ás-Cardama A,Kantarjian HM,Manshouri T,et al.Lenalidomide plus prednisone results in durable clinical,histopathologic,and molecular responses in patients with myelofibrosis.J Clin Oncol,2009,27:4760-4766.
  • 7Chee L,Kalnins R,Turner P.Low dose melphalan in the treatment of myelofibrosis:a single centre experience.Leuk Lymphoma,2006,47:1409-1412.
  • 8Mishchenko E,Tefferi A.Treatment options for hydroxyurea-refractory disease complications in myeloproliferative neoplasms:JAK2inhibitors,radiotherapy,splenectomy and transjugular intrahepatic portosystemic shunt.Eur J Haematol,2010,Jun 2.[Epub ahead of print].
  • 9Tefferi A,Verstovsek S,Barosi G,et al.Pomalidomide is active in the treatment of anemia associated with myelofibrosis.J Clin Oncol,2009,27:4563-4569.
  • 10Barosi G,Bordessoule D,Briere J,et al.Response criteria for myelofibrosis with myeloid metaplasia:results of an initiative of the European Myelofibrosis Network (EUMNET).Blood,2005,106:2849-2853.

共引文献13

同被引文献49

  • 1刘恩彬,陈辉树,邱录贵.淋巴瘤侵犯骨髓的病理与临床研究进展[J].诊断病理学杂志,2004,11(3):196-198. 被引量:21
  • 2孙碧红,曾维平,闭艺芳.骨髓活检与涂片对非霍奇金淋巴瘤骨髓浸润诊断价值的比较[J].广西医科大学学报,2003,20(4):505-506. 被引量:3
  • 3罗莉,罗小华,孙汉英,徐慧珍,路武.继发于恶性肿瘤骨髓纤维化症47例临床资料分析[J].中国血液流变学杂志,2005,15(4):603-605. 被引量:6
  • 4Burkhardt B,Reiter A,Landmann E,et al.Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma:a report from the Berlin-Frankfurt-Muenster Group.J Clin Oncol,2009;27(10):3363-3369.
  • 5Nielo LH,Raya Sanchez JM,Arguelles HA,et al.A case of chronic lymphocytic leukemia overwhelmed by rapidly progression idiopathic myelofibrosis.Haematologica,2000;85(9):973-977.
  • 6Kikukawa M,Umahara T,Kikawada M,et al.Peripheral T-cell lymphoma presenting as myelofibrosis with the expression of basic fibroblast growth factor.Geriatr Gerontol Int,2009;9(4):395-398.
  • 7Okabe S,Miyazawa K,Lguchi T,et al.Peripheral T-cell lymphomatogether with myelofibrosis with elevated plasma transforming growth factor-β1.Leuk Lymphoma,2005;46(4):599-602.
  • 8Matsunaga T,Takemoto N,Miyajima N,et al.Splenic marginal zone lymphoma presenting as myelofibrosis associated with bone marrow involvement of lymphoma cells which secrete a large amount of TGF beta.Ann Hematol,2004;83(5):322-325.
  • 9Matsui I,Adachi M,Tominaga T,et al.Angioimmunoblastic T cell lymphoma associated with reversible myelofibrosis.Intem Med,2008;47(21):1921-1924.
  • 10Mohren M,Essbach U,Franke A,et al.Acute myelofibrosis in a patient with diffuse large cell non Hodgkin's lymphoma and renal cancer.Leuk Lymphoma,2003;44(9):1603-1607.

引证文献8

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部